PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Por um escritor misterioso
Descrição
Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177- PSMA-617 radioligand therapy, BMC Urology
Cancers, Free Full-Text
Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? - ScienceDirect
Computed tomographic images at the the middle third lumbar vertebral
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - ScienceDirect
3-Year Freedom from Progression After 68Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
Computed tomographic images at the the middle third lumbar vertebral
Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts - The Lancet Public Health
de
por adulto (o preço varia de acordo com o tamanho do grupo)